Clinical trial NCT00654758: A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)
Official title: A Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of Volociximab (M200) in Combination With Carboplatin and Paclitaxel in Subjects With Previously Untreated Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Non-small Cell Lung Cancer
Keywords: cancer
carcinoma
chemotherapy
monoclonal antibody therapy
anti-angiogenesis
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2008-04-09
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to examine the safety of volociximab in combination with a standard treatment of carboplatin and paclitaxel in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC).

Detailed description: This Phase 1b, multicenter, open-label, dose-escalation study will evaluate the safety and pharmacokinetics (PK) of volociximab in combination with carboplatin and paclitaxel (C/P) as first-line treatment in subjects with Stage IIIB or IV non-small cell lung cancer (NSCLC). Volociximab doses of 10, 20, and 30 mg/kg (or 15 mg/kg if 20 mg/kg is not tolerable) with carboplatin/paclitaxel chemotherapy will be tested for determining the maximum tolerated dose (MTD). Subjects will be dosed once very 3 weeks for up to 6 cycles.

Volociximab is a high-affinity, chimeric monoclonal antibody that specifically binds to α5β1 integrin, a cell-surface receptor for fibronectin. Volociximab blocks the binding of α5β1 to fibronectin, thereby inhibiting a pivotal interaction required for angiogenesis.

More than 170 subjects with various solid tumor types have received volociximab in Phase 1 and Phase 2 single and combination studies. At the doses tested, there has not been a dose limiting toxicity (DLT) or a maximum tolerated dose (MTD) defined.

Eligibility criteria: Inclusion Criteria

1. Males and females at least 18 years of age.
2. Stage IIIB or IV or recurrent NSCLC.
3. Measurable and/or evaluable disease according to RECIST.
4. No prior chemotherapy, biological therapy or immunotherapy for Stage IIIB/IV disease. Adjuvant therapy for early stage disease must have been completed \> or = 6 months prior to Cycle 1, Day 1 of this study.
5. Eastern Cooperative Oncology Group (ECOG) performance status \< or =1.
6. A negative pregnancy test (serum or urine) in women of childbearing potential at screening.

Exclusion Criteria

1. Known allergy or sensitivity to murine proteins, chimeric antibodies or other components of the product, Cremophor EL (polyoxyethylated castor oil), cisplatin, or other platinum-containing compounds.
2. Absolute neutrophil count (ANC) \<1500/mm3, hemoglobin level \<9 g/dL, or a platelet count \<100,000/mm3.
3. Aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphatase values of .2.5 of the upper limits of normal values (ULN) (\>5 ULN for subjects with liver metastases) or alkaline phosphatase values \>2.5 ULN (unless documented bone metastases are responsible for the increase of alkaline phosphatase); total bilirubin \>1.5 mg/dL, or serum creatinine \>1.8 mg/dL.
4. Radiation therapy within 1 month before Cycle 1, Day 1.
5. Documented symptomatic central nervous system (CNS) tumor or CNS metastases.
6. History of thromboembolic events, including cardiovascular or cerebrovascular events (ie, acute myocardial infarction \[AMI\], stroke) within 1 year prior to Cycle 1, Day 1.
7. History of known bleeding disorders and coagulation defects.
8. History of significant hemoptysis (ie, \> or =1/2 teaspoon red blood per event) or gastrointestinal bleeding within 1 year prior to Cycle 1, Day 1.
9. Major surgery (eg, exploratory laparotomy) within 4 weeks prior to Cycle 1, Day 1 of the study.
10. Clinically significant or unstable medical conditions including, but not limited to, uncontrolled diabetes mellitus requiring insulin, uncontrolled hypertension, or uncontrolled or symptomatic orthostatic hypotension.
11. Oxygen-dependent chronic obstructive pulmonary disease.
12. Known active infections requiring intravenous (IV) antibiotics, antivirals, or antifungals, including but not limited to chronic human immunodeficiency virus, hepatitis B, or hepatitis C infection.
13. Prior bone marrow or stem cell transplant.

Primary outcomes:
measure: To determine the maximum tolerated dose (MTD) of volociximab given at different doses in combination with carboplatin and paclitaxel
timeFrame: Dose escalation phase of the trial
Secondary outcomes:
measure: Pharmacokinetics of volociximab
timeFrame: Approximately 2.5 years
measure: Efficacy of volociximab in combination with carboplatin/paclitaxel
timeFrame: Approximately 2.5 years
Other outcomes:
Locations:
Study officials:
affiliation: Abbott
name: Mihail Obrocea, MD
role: STUDY_DIRECTOR
References:
citation: Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, Belani CP. Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol. 2013 Jan;24(1):90-6. doi: 10.1093/annonc/mds281. Epub 2012 Aug 16.